FDA
-
-
-
-
-
-
-
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
-
-
-
-
-
-
-
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
-
-
-
-
-
-
-
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
-
-
-
-
-
-
-
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
-
-
-
-
-
-
-
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
-
-
-
-
-
-
-
Turnstone Biologics Appoints William Waddill to its Board of Directors
-
-
-
-
-
-
-
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

